Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPhA Objection To Generic Drug Rule Could Backfire, FDA Counsel Troy Warns

This article was originally published in The Tan Sheet

Executive Summary

The generic drug industry should carefully consider any attempt to derail FDA's regulatory approach to Hatch/Waxman reform, agency Chief Counsel Daniel Troy told the Generic Pharmaceutical Association
Advertisement

Related Content

FDA Adds Patent Declaration Forms For Innovators To Generic Final Rule
FDA Adds Patent Declaration Forms For Innovators To Generic Final Rule
FDA Adds Patent Declaration Forms For Innovators To Generic Final Rule
30-Month Stay Proposal Would Delay Generics, Should Be Withdrawn, GPhA Says
FDA Patent Listing Criteria Allow Polymorph, Product-By-Process Claims
FDA Patent Listing Criteria Allow Polymorph, Product-By-Process Claims
FDA Review Standards “Inconsistent” For New Drugs, Generics, PhRMA Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS095112

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel